The Evaluation of Patients with Severe COVID-19 Pneumonia Who are Recieving Favipiravir Treatment
Introduction: There is no known specific treatment for Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). Our retrospective study evaluates the effectiveness of steroid treatment and the factors affecting treatment in patients with severe Coronavirus disease-2019 (COVID-19) pneumonia that...
Saved in:
| Main Authors: | Servet ÖZTÜRK, Onur ÇOLAK, Semra KAVAS, Derya ÖZTÜRK ENGİN, Serap DİKTAŞ TAHTASAKAL, Dilek ERDOĞAN ARI, Öznur DEMİROLUK, Berna ÖZDEMİR, Büşra Meral ÇETİNKAYA, Merve KAÇAR EKER, İrem Asena DOĞAN, Haluk VAHABOĞLU, Canan AĞALAR |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2021-12-01
|
| Series: | Mediterranean Journal of Infection, Microbes and Antimicrobials |
| Subjects: | |
| Online Access: | http://mjima.org/abstract.php?id=238 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Favipiravir for the treatment of COVID-19 pneumonia: Can we predict the response to treatment?
by: Abdullah Sayiner, et al.
Published: (2022-03-01) -
Efficacy of favipiravir in COVID-19: A retrospective two center comparative study
by: Elif Tukenmez Tigen, et al.
Published: (2024-09-01) -
Phase I Pharmacokinetics Study of Drug for Infusion «Areplivir» (INN: Favipiravir) (LLC "PROMOMED RUS", Russia)
by: T. N. Komarov, et al.
Published: (2023-05-01) -
Reciprocal Impact of Molnupiravir and Favipiravir Monocomponents of the Combination Drug on Each Other's Pharmacokinetics in a Phase I Clinical Trial
by: T. N. Komarov, et al.
Published: (2024-03-01) -
Phase I Pharmacokinetics Study of Drug Areplivir® Zinc (INN: Favipiravir + Zinc Gluconate) (LLC "PROMOMED RUS", Russia)
by: T. N. Komarov, et al.
Published: (2024-03-01)